Staphylococcus aureus is a significant cause of a wide range of infectious diseases in humans and can cause life-threatening infection. Despite advances in diagnosis and treatment, S. aureus remains a troubling pathogen with increasing prevalence throughout the world.
In the United States, the National Nosocomial Infections Surveillance System (NNIS) reported that the pooled mean rate of antimicrobial resistance among intensive care unit patients with nosocomial S. aureus infection was 40% higher in 1999 than in [1994] [1995] [1996] [1997] [1998] [1]. Furthermore, in 2002, 155% of nosocomial infections in patients in intensive care units were due to methicillin-resistant S. aureus (MRSA) [2, 3] . In Canada, hospitals participating in the Canadian Nosocomial Infection Surveillance Program reported an increase in the rate of MRSA infection, from 0.46 cases per 1000 admissions in 1995 to 5.1 cases per 1000 admissions in 2003 [4] .
A European study found that the prevalence of MRSA significantly increased from 1999 through 2002 in Belgium, Germany, Ireland, The Netherlands, and the United Kingdom and decreased in Slovenia [5] . In England, data from acute care National Health Service hospitals indicate a small increase in the total number of S. aureus infections, from 17 MRSA infections are increasing throughout the world. A recent study showed that, with the spread of MRSA infection, the total number of patients affected by S. aureus has increased, adding to the total economic burden associated with the disease [7] . Although US and international data are available on historical trends for MRSA, estimates of the infection rate, economic burden, and mortality of S. aureus infection-which may include both methicillin-susceptible S. aureus (MSSA) infection and MRSA infection-in general are limited. The aging population and the prevalence of other risk factors for S. aureus infection, such as diabetes, suggest that the burden of S. aureus to US hospitals may have increased [8] [9] [10] . In addition, the increasing spread of MRSA in the community may also have an impact on the burden of S. aureus infections in US hospitals [11] [12] [13] [14] [15] [16] [17] [18] .
The objective of our study was to evaluate national trends in the S. aureus infection rate, in the S. aureus-related economic burden, and in the S. aureus-related in-hospital mortality risk in US hospitals during the 6-year period 1998-2003.
METHODS
We conducted a retrospective analysis of the Agency for Healthcare Research and Quality's Nationwide Inpatient Sample (NIS) database [19] . The NIS data have been previously used to estimate the national S. aureus infection rate and economic burden of S. aureus infection to hospitals [20] . The NIS is the largest all-payer inpatient health care database in the United States, containing data from ∼7 million hospital stays annually, and it has high external validity.
NIS data from a 6-year period that included 1998-2003 were used to assess trends over time. All discharge data were captured for each year, to total ∼45 million discharge records. Although there have been sample design changes in NIS over the years, methodological techniques and appropriate adjustments were applied for unbiased assessment of trends over time [21] . Patient characteristics included age, sex, race, and type of insurance.
Identification of S. aureus infection stays. For each year of the NIS data, all the hospital discharges were classified as either a S. aureus-related infection stay or a S. aureus-unrelated infection stay. A combination of several diagnosis codes from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), was used to identify S. aureus infections in the NIS database. A hospital stay was considered to be related to S. aureus infection if the discharge codes had either (1) an S. aureus-specific infection code (038.11 or 482.41) or (2) the S. aureus microorganism code (041.11) in conjunction with an indication that infection was possibly due to S. aureus. The method of identification of S. aureus-related hospital stay is described in more detail in a previous study [20] .
Patient stay strata. Monitoring trends across subpopulations can demonstrate substantial changes that would be obscured if all data were aggregated. Hospital discharges were therefore analyzed through a framework of 5 different strata of hospital stays: all inpatient stays, surgical stays, invasive cardiovascular surgical stays, invasive orthopedic surgical stays, and invasive neurosurgical stays. Clinically similar operative procedures were identified on the basis of the methods described by the NNIS system of the Centers for Disease Control and Prevention (CDC) [3] .
Analytical approach. Data were analyzed using SAS software, version 9 (SAS Institute), and the Joinpoint Regression Program, version 3.0 (Statistical Research and Applications Branch, National Cancer Institute). Statistical significance was assessed at an a priori a level of .05. All analyses included sample weights that account for the complex design of the NIS data, including the unequal probabilities of selection, oversampling, and nonresponse.
For each year, the annual prevalence of S. aureus infections was calculated. The incremental marginal effects of S. aureus infection on hospital charges and in-hospital mortality rate were estimated using multivariate regression models that accounted for the complex design and sampling methods of the NIS data. We used Proc Surveyreg for charges and Proc Surveylogistic for mortality (both in SAS software, version 9.0), controlling for hospital fixed effects and patient variables, including age, sex, race, payer, diagnosis-related grouping, as well as presence of diabetes, use of dialysis, and presence of lung disease. The concomitant conditions controlled for in the multivariate analysis were identified in a previous study [20] .
The annual economic burden of S. aureus infection to hospitals in the United States was calculated by multiplying the number of S. aureus infection discharges by the incremental effect of S. aureus infection on hospital charges. The 95% CIs around the annual economic burden of S. aureus for each year were simulated using Monte Carlo simulation methods. All charges for each of the years were converted to the year 2004 US dollars via the Consumer Price Index for Medical Care, Hospital, and Related Services [22] . It should be noted that charges are not the same as the cost for an inpatient stay: charges include hospital overhead costs, charity care, and bad debt, among other costs, in addition to the actual costs of providing the care.
The marginal estimates derived by the multivariate regression model analyses for incremental charges and in-hospital mortality risk were used as inputs in Joinpoint trends analysis. Joinpoint regression analysis describes trend data by a number of contiguous linear segments and "joinpoints" (points at which trends change). The analysis helps to estimate the annual percentage change in each outcome and the number and location of joinpoints [23] . The joinpoint models are based on linear regression, with log of the outcomes as the dependent variable and year as the independent variable. Because the current analysis had only 6 data points for the 6-year period (1998) (1999) (2000) (2001) (2002) (2003) , the maximum number of joinpoints tested was 1. Adjusted incremental impact of S. aureus infection on inhospital mortality risk. The incremental impact of S. aureus infection-related stays, compared with S. aureus infection-unrelated stays, on the absolute risk of in-hospital mortality was similar among all inpatient stays and surgical stays (table 3) . Among invasive cardiovascular surgical stays, the absolute risk of in-hospital mortality due to S. aureus infection was higher than that for the other patient strata types, at 8.5% in 1998 and 9.5% in 2003.
RESULTS
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Historical trends in prevalence of S. aureus infection. ). P p .008 Historical trends in in-hospital mortality due to S. aureus infection. S. aureus infection-related absolute risk for in-hospital mortality showed a decreasing trend among all inpatient stays and surgical stays, whereas the risk remained stable for other patient stay types (table 4). The absolute risk for S. aureus infection-related in-hospital mortality decreased significantly from 1998 to 2003, at an annual rate of 4.6% ( ) and P p .001 4.6% ( ), among all inpatient stays and surgical stays, P p .002 respectively. Among invasive orthopedic surgical stays and neurosurgical stays, the absolute risk of S. aureus infection-related in-hospital mortality also showed a decreasing trend, although the annual change was not statistically significant.
DISCUSSION
During the 6-year period 1998-2003, across the different patient stay types, the prevalence of S. aureus infection in US hospitals increased at an annual rate ranging from 7.1% to 11.0%. The rate of increase in the prevalence was greatest for invasive orthopedic surgical stays (53.5% from 1998 to 2003). Similar trends in S. aureus infection rates have been observed in other countries [14, 24, 25] . The historical increases in the prevalence of inpatient S. aureus infection observed in this study may reflect improved detection and reporting practices. Although hospitals may not have financial incentives to determine S. aureus-specific codes, increased awareness among physicians and hospitals might have led to improved coding of S. aureus infection among hospitalized patients.
S. aureus infection entails substantial hospital expenditures. The total annual economic burden of S. aureus infection in 2004 US dollars among all inpatient stays was $8.7 billion in 1998, and it increased to $14.5 billion in 2003. Trends in economic burden of S. aureus infections to US hospitals were positive and statistically significant for all the patient stay types.
An interesting finding in this study was a decreasing trend in absolute risk of in-hospital mortality due to S. aureus infection during the 6-year study period. This decrease in trend was significant among all inpatient stays and all surgical stays; however, it was not significant among invasive orthopedic, cardiovascular or neurosurgical stays. This finding is contrary to recent estimates suggesting an increased attributable mortality of MRSA relative to MSSA among S. aureus infections [2, 4, [26] [27] [28] [29] [30] . Additional investigations are needed to better understand and explore this association. In our data, the proportion of patients with S. aureus infection-associated stays who were discharged to other types of facilities, such as nursing homes, or to home health care did not change substantially from 1998 to 2003, 46.0% in 1998 and 47.3% in 2003, indicating that the observed decrease in in-hospital mortality risk is unlikely to be confounded by discharge status.
The observed decrease in in-hospital mortality risk may be associated with the introduction of more stringent infectioncontrol programs or with appropriate early treatment of MRSA infections with vancomycin [31] . There are very limited data on the impact of S. aureus infections on in-hospital mortality with which to compare our results. Typically, mortality caused by S. aureus is not routinely reported, because trends in mortality are monitored using the underlying cause of death, and the infection itself is rarely the underlying cause of death. Studies conducted in England and Wales reported that mortality due to MRSA infection increased from 1993 to 2002 [32, 33] . It should be noted that the annual, in-hospital, same-stay mortality risk reported in this study is not directly comparable to the trend in crude mortality rate observed in England and Wales, because the current data are based on mortality during a single hospital admission event.
The present study has several limitations. First, S. aureus infections and comorbidities of interest were identified using ICD-9-CM codes. Therefore, results depended on the sensitivity and specificity of identification of S. aureus infection using ICD-9-CM coding in the NIS database. However, these methods have been used in a previous study [20] . Related to this is the possibility of changes in ICD-9-CM coding practices in hospitals from year to year may have had an indirect impact on the measured prevalence or the observed trends. However, because the set of ICD-9-CM diagnosis codes used to identify S. aureus infections did not change during the 6 years of this study, this event is unlikely. There is limited reason to suspect a change in hospital coding practices, given that there were no major changes in the related ICD-9-CM codes during the 6-year study period.
Another design limitation of this study was the inability to classify S. aureus infections into those due to MRSA or MSSA. The ICD-9-CM diagnoses codes used in this study do not allow for further classification of S. aureus infections into the specific strains of microorganisms. As has been highlighted earlier, there is evidence of a growing prevalence of MRSA relative to MSSA among S. aureus infections [2, 4] . Studies have also demonstrated a relatively larger negative impact on outcomes of length of stay, costs, and mortality among MRSA infections, compared with MSSA infections [26] [27] [28] [29] [30] . The economic burden of S. aureus infection reported in this study reflects a nationally representative weighted mix of S. aureus infection strains observed in US hospitals. However, it is recommended that, in the future, ICD-9-CM diagnoses codes could be made available that allow for reliable identification of specific strains of S. aureus, for better epidemiological and health outcome tracking in administrative databases.
By design, the NIS data represent health care utilization during a single hospital admission event. All of the patients' personal identifying information is eliminated to protect the confidentiality of patients. Therefore, the data do not allow researchers to identify and evaluate follow-up hospitalizations, transfers, and mortality due to S. aureus after hospital discharge. Because the scope of the patient-level observation in the NIS is limited to 1 hospital stay, the burden evaluated in this study is the in-hospital burden only.
Related to this, it was also not possible to use the NIS data to determine whether a patient already had S. aureus infection before entering the hospital setting (community-acquired S. aureus infection) or at what point during a hospital stay the patient developed S. aureus infection. In other words, it was not possible to discern whether the infection was prevalent or incident. Because the NIS data available on a given record represent summary information for that hospital stay and do not allow for observing the sequence of events within that stay, each record therefore approximates a "point in time" or crosssectional observation. For this reason, we report the infection rates as prevalences and not incidences. During the past few years, an increased prevalence of community-associated MRSA infection has been reported [14, 15] . Mathematical models have shown that community-acquired MRSA has a high potential to become endemic in the community, and this will likely impact the control of MRSA infection in the hospital setting [13] . Nevertheless, in this study, within the specific patient stay types investigated (i.e., surgery, invasive cardiovascular surgery, invasive orthopedic surgery, and invasive neurosurgery stays), it is likely that most of the infections caused by S. aureus would be nosocomial in nature.
Despite the data and coding limitations that are common to all administrative data, the NIS remains the best and most current source for nationwide population-based trends in inpatient burden of S. aureus infections. This study leveraged the large number of records in the NIS data sets (∼45 million hospital discharges over a 6-year period) that allowed for the derivation of trend estimates while controlling for potential confounding variables.
In conclusion, our findings indicate that the inpatient S. aureus infection rate and economic burden of S. aureus infections to US hospitals increased considerably from 1998 to 2003, whereas the risk of in-hospital mortality remained stable or even decreased during this period. The study results highlight the pressing need for implementation of the 2007 Joint Commission on Accreditation of Healthcare Organizations National Hospital Patient Safety Goal number 7: to reduce the risk of health care-associated infection [34] . The Joint Commission recommends complying with current CDC hand hygiene guidelines and managing as sentinel events all identified cases of unanticipated death or major permanent loss of function associated with a health care-associated infection [34] . Results derived from this study could be used to create a forecasting model to estimate future trends in prevalence and burden of S. aureus infections for hospitals in the United States.
